159 related articles for article (PubMed ID: 38201278)
21. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
22. Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition.
Abildgaard C; Dahl C; Basse AL; Ma T; Guldberg P
J Transl Med; 2014 Sep; 12():247. PubMed ID: 25182332
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
Shulak L; Beljanski V; Chiang C; Dutta SM; Van Grevenynghe J; Belgnaoui SM; Nguyên TL; Di Lenardo T; Semmes OJ; Lin R; Hiscott J
J Virol; 2014 Mar; 88(5):2927-40. PubMed ID: 24371063
[TBL] [Abstract][Full Text] [Related]
24. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
25. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.
Wang J; Chen J; Miller DD; Li W
Mol Cancer Ther; 2014 Jan; 13(1):16-26. PubMed ID: 24249714
[TBL] [Abstract][Full Text] [Related]
26. Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Fragale A; Stellacci E; Romagnoli G; Licursi V; Parlato S; Canini I; Remedi G; Buoncervello M; Matarrese P; Pedace L; Ascione B; Pizzi S; Tartaglia M; D'Atri S; Presutti C; Capone I; Gabriele L
Int J Cancer; 2023 Sep; 153(5):1080-1095. PubMed ID: 37293858
[TBL] [Abstract][Full Text] [Related]
27. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
29. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
30. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M; Schaack D; Grekova SP; Bauer AS; Giese T; Salg GA; Espinet E; Leuchs B; Heller A; Nüesch JPF; Schenk M; Volkmar M; Giese NA
Viruses; 2021 May; 13(6):. PubMed ID: 34071585
[TBL] [Abstract][Full Text] [Related]
31. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.
Han S; Ren Y; He W; Liu H; Zhi Z; Zhu X; Yang T; Rong Y; Ma B; Purwin TJ; Ouyang Z; Li C; Wang X; Wang X; Yang H; Zheng Y; Aplin AE; Liu J; Shao Y
Nat Commun; 2018 Jan; 9(1):28. PubMed ID: 29295999
[TBL] [Abstract][Full Text] [Related]
32. Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release.
Zhang T; Essani K
Virus Genes; 2017 Jun; 53(3):477-482. PubMed ID: 28188458
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.
Radić M; Vlašić I; Jazvinšćak Jembrek M; Horvat A; Tadijan A; Sabol M; Dužević M; Herak Bosnar M; Slade N
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077308
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.
Corazao-Rozas P; Guerreschi P; Jendoubi M; André F; Jonneaux A; Scalbert C; Garçon G; Malet-Martino M; Balayssac S; Rocchi S; Savina A; Formstecher P; Mortier L; Kluza J; Marchetti P
Oncotarget; 2013 Nov; 4(11):1986-98. PubMed ID: 24161908
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic viruses in melanoma.
Robinson C; Xu MM; Nair SK; Beasley GM; Rhodin KE
Front Biosci (Landmark Ed); 2022 Feb; 27(2):63. PubMed ID: 35227006
[TBL] [Abstract][Full Text] [Related]
36. RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Data Brief; 2020 Jun; 30():105610. PubMed ID: 32382617
[TBL] [Abstract][Full Text] [Related]
37. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
Kohlhapp FJ; Kaufman HL
Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
[TBL] [Abstract][Full Text] [Related]
38. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Roos WP; Quiros S; Krumm A; Merz S; Switzeny OJ; Christmann M; Loquai C; Kaina B
Oncotarget; 2014 Dec; 5(24):12607-20. PubMed ID: 25557167
[TBL] [Abstract][Full Text] [Related]
39. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.
Kemper K; Krijgsman O; Cornelissen-Steijger P; Shahrabi A; Weeber F; Song JY; Kuilman T; Vis DJ; Wessels LF; Voest EE; Schumacher TN; Blank CU; Adams DJ; Haanen JB; Peeper DS
EMBO Mol Med; 2015 Sep; 7(9):1104-18. PubMed ID: 26105199
[TBL] [Abstract][Full Text] [Related]
40. SOX10-MITF pathway activity in melanoma cells.
Tudrej KB; Czepielewska E; Kozłowska-Wojciechowska M
Arch Med Sci; 2017 Oct; 13(6):1493-1503. PubMed ID: 29181082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]